- Home
- FMY vs DRRX Comparison
FMY vs DRRX Comparison
Compare FMY & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- DRRX
- Stock Information
- Founded
- FMY 2005
- DRRX 1998
- Country
- FMY United States
- DRRX United States
- Employees
- FMY N/A
- DRRX N/A
- Industry
- FMY Finance/Investors Services
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- FMY Finance
- DRRX Health Care
- Exchange
- FMY Nasdaq
- DRRX Nasdaq
- Market Cap
- FMY 50.5M
- DRRX 59.0M
- IPO Year
- FMY N/A
- DRRX 2000
- Fundamental
- Price
- FMY $12.15
- DRRX $1.91
- Analyst Decision
- FMY
- DRRX Hold
- Analyst Count
- FMY 0
- DRRX 1
- Target Price
- FMY N/A
- DRRX N/A
- AVG Volume (30 Days)
- FMY 10.1K
- DRRX 2.9M
- Earning Date
- FMY 01-01-0001
- DRRX 08-12-2025
- Dividend Yield
- FMY 6.98%
- DRRX N/A
- EPS Growth
- FMY N/A
- DRRX N/A
- EPS
- FMY N/A
- DRRX N/A
- Revenue
- FMY N/A
- DRRX $1,657,000.00
- Revenue This Year
- FMY N/A
- DRRX N/A
- Revenue Next Year
- FMY N/A
- DRRX $673.00
- P/E Ratio
- FMY N/A
- DRRX N/A
- Revenue Growth
- FMY N/A
- DRRX N/A
- 52 Week Low
- FMY $10.71
- DRRX $0.48
- 52 Week High
- FMY $12.17
- DRRX $2.64
- Technical
- Relative Strength Index (RSI)
- FMY 44.25
- DRRX 84.64
- Support Level
- FMY $12.17
- DRRX $1.85
- Resistance Level
- FMY $12.33
- DRRX $1.92
- Average True Range (ATR)
- FMY 0.06
- DRRX 0.09
- MACD
- FMY -0.02
- DRRX 0.01
- Stochastic Oscillator
- FMY 0.00
- DRRX 10.98
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.